Blueprint Medicines (NASDAQ:BPMC) Price Target Raised to $75.00 at HC Wainwright

Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its price objective hoisted by HC Wainwright from $70.00 to $75.00 in a research report report published on Friday morning, The Fly reports. Several other research analysts also recently commented on BPMC. SVB Securities dropped their target price on shares of Blueprint Medicines from $45.00 to $38.00 in […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Brian Druker ,Chris Varma ,Raymond James ,Nicholasb Lydon ,Christina Rossi ,Jeffreyw Albers ,Blueprint Medicines Corp ,Proficio Capital Partners ,Morgan Stanley ,Associates Corp ,Nisa Investment Advisors ,Lazard Asset Management ,Blueprint Medicines ,Get Rating ,Moderate Buy ,Director Jeffrey ,Capital Partners ,Asset Management ,Investment Advisors ,Quantbot Technologies ,Alexis Borisy ,Blueprint Medicines Daily ,Nasdaq Bpmc ,Bpmc ,Medical ,Boost Price Target ,Hc Wainwright ,